Development and validation of a risk score for detecting non-alcoholic fatty liver disease.

IF 1.3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Zhili Jiang, Xiang Li, Duo Yang, Chao Qu, Jiayi Yi, Hai Gao
{"title":"Development and validation of a risk score for detecting non-alcoholic fatty liver disease.","authors":"Zhili Jiang, Xiang Li, Duo Yang, Chao Qu, Jiayi Yi, Hai Gao","doi":"10.1097/MD.0000000000040417","DOIUrl":null,"url":null,"abstract":"<p><p>The development of an easy-to-use noninvasive model to screen nonalcoholic fatty liver disease (NAFLD) is warranted. This study aimed to develop and validate a simple noninvasive NAFLD risk score (NARS). We used the National Health and Nutrition Examination Survey 2017 to March 2020 cycle data. The sample size of derivation and validation cohort were 4056 and 2502, separately. The NAFLD was determined by FibroScan® measured controlled attenuation parameter scores of >285 dB/m in the absence of excessive alcohol use, steatogenic medications use, and viral hepatitis. The NARS was derived from a multivariable logistic regression model and variables were selected based on Boruta analysis. The performance of NARS was internally validated and compared with previous models using receiver-operating characteristics curve and C-statistics. The NARS was established using waist circumference, triglycerides, alanine aminotransferase, and fasting glucose, and the total score ranges from 0 to 8, with an increasing risk of NAFLD. NARS demonstrated ideal discrimination in the validation cohort, with C-statistics of 0.832 (95% confidence interval, 0.801-0.824), and was not inferior to any existing models. The optimal cutoff point for predicting NAFLD was obtained at 4 scores with a sensitivity of 82% and specificity of 69%. We reported the derivation and internal validation of a novel and easy-to-use risk score for detecting the presence of NAFLD. NARS demonstrated ideal discrimination performance and was practical in clinical practice for selecting individuals at higher risk of NAFLD for further examination or intervention.</p>","PeriodicalId":18549,"journal":{"name":"Medicine","volume":"103 46","pages":"e40417"},"PeriodicalIF":1.3000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575981/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MD.0000000000040417","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

The development of an easy-to-use noninvasive model to screen nonalcoholic fatty liver disease (NAFLD) is warranted. This study aimed to develop and validate a simple noninvasive NAFLD risk score (NARS). We used the National Health and Nutrition Examination Survey 2017 to March 2020 cycle data. The sample size of derivation and validation cohort were 4056 and 2502, separately. The NAFLD was determined by FibroScan® measured controlled attenuation parameter scores of >285 dB/m in the absence of excessive alcohol use, steatogenic medications use, and viral hepatitis. The NARS was derived from a multivariable logistic regression model and variables were selected based on Boruta analysis. The performance of NARS was internally validated and compared with previous models using receiver-operating characteristics curve and C-statistics. The NARS was established using waist circumference, triglycerides, alanine aminotransferase, and fasting glucose, and the total score ranges from 0 to 8, with an increasing risk of NAFLD. NARS demonstrated ideal discrimination in the validation cohort, with C-statistics of 0.832 (95% confidence interval, 0.801-0.824), and was not inferior to any existing models. The optimal cutoff point for predicting NAFLD was obtained at 4 scores with a sensitivity of 82% and specificity of 69%. We reported the derivation and internal validation of a novel and easy-to-use risk score for detecting the presence of NAFLD. NARS demonstrated ideal discrimination performance and was practical in clinical practice for selecting individuals at higher risk of NAFLD for further examination or intervention.

开发并验证用于检测非酒精性脂肪肝的风险评分。
有必要开发一种易于使用的无创模型来筛查非酒精性脂肪肝(NAFLD)。本研究旨在开发并验证一种简单的非酒精性脂肪肝风险评分(NARS)。我们使用了 2017 年至 2020 年 3 月的全国健康与营养调查周期数据。衍生队列和验证队列的样本量分别为 4056 人和 2502 人。在没有过度饮酒、服用致脂肪药物和病毒性肝炎的情况下,非酒精性脂肪肝的判定标准是 FibroScan® 测得的控制衰减参数分数>285 dB/m。NARS 由一个多变量逻辑回归模型得出,变量的选择基于 Boruta 分析。NARS 的性能经过了内部验证,并使用接收者工作特征曲线和 C 统计量与之前的模型进行了比较。NARS 是利用腰围、甘油三酯、丙氨酸氨基转移酶和空腹血糖建立的,总分在 0-8 之间,非酒精性脂肪肝的风险越高。NARS 在验证队列中显示出理想的分辨能力,C 统计量为 0.832(95% 置信区间,0.801-0.824),不逊于任何现有模型。预测非酒精性脂肪肝的最佳临界点为 4 分,灵敏度为 82%,特异度为 69%。我们报告了一种新颖易用的非酒精性脂肪肝检测风险评分的推导和内部验证。NARS 具有理想的鉴别性能,在临床实践中非常实用,可用于选择非酒精性脂肪肝的高危人群进行进一步检查或干预。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medicine
Medicine 医学-医学:内科
CiteScore
2.80
自引率
0.00%
发文量
4342
审稿时长
>12 weeks
期刊介绍: Medicine is now a fully open access journal, providing authors with a distinctive new service offering continuous publication of original research across a broad spectrum of medical scientific disciplines and sub-specialties. As an open access title, Medicine will continue to provide authors with an established, trusted platform for the publication of their work. To ensure the ongoing quality of Medicine’s content, the peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信